Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Theravance Biopharma, Inc.NASDAQ: TBPH

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $1.44M rose 247.9% year over year, ahead of the +91.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.

Context

  • Depreciation & amortization amounted to 5.1% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +247.9% holds above the trailing-twelve-month pace of +91.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.44M-4.6% QoQ
Last fiscal yearDec 2025
$5.52M+52.6% YoY
LTMMar 2026
$3.76M+91.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+247.9%——
1 year+52.6%——
3-year CAGR+22.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
5.52M USD
Year-over-year change
+52.6%
4-year CAGR
+3.5%

Depreciation & Amortization vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +91.5% is the 2nd highest of 8, against a peer median of -10.0%.
  • Depreciation & amortization amounts to 3.4% of revenue for TBPH, versus a peer median of 4.1%.
TBPH Competitors
Depreciation & Amortization for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$8.34M USD+0.8%+30.7%19.4%
VALNValneva SELTM Mar 2026€6.46M EUR-64.9%+1.1%4.1%
TBPHTheravance Biopharma, Inc.LTM Mar 2026$3.76M USD+91.5%+22.0%3.4%
REPLReplimune Group, Inc.LTM Dec 2025$3.61M USD-34.2%+9.0%—
GERNGeron CorporationLTM Mar 2026$1.04M USD-17.2%+11.5%0.5%
TYRATyra Biosciences, Inc.LTM Mar 2026$541K USD+0.2%+22.6%—
LENZLENZ Therapeutics, Inc.LTM Mar 2026$362K USD+306.7%+229.8%1.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding TBPH) —-10.0%+19.9%4.1%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.